Skip to content
OpenCapital
Get started

NTHI NTHI Outstanding Amounts Payable To Usc For Clinical Trial Services

Other financials

Income statement

See full
Revenue$40.0K-7.0%
Operating income-$7.1M+77.9%
Net income-$8.8M+72.7%
EPS (diluted)-$0.38+78.7%

Balance sheet

See full
Cash & equivalents$138.6K-97.5%
Total debt$666.1K—
Total equity-$13.2M-37.5%
Total assets$3.3M-60.6%

Cash flow

See full
Operating cash flow-$7.0M-23.7%
CapEx$125.0K—
Free cash flow-$5.2M—

Valuation

See full
Market cap$114.62M+51.0%
Enterprise value$115.15M+51.1%
P/S1,432.9×—

Profitability

See full
Operating margin-46,870.7%—
Net margin-51,613.3%—
FCF margin-26,083.2%—

Returns & leverage

See full
Return on equity338.1%—
Debt / equity-0.1×—
Current ratio0.1×-0.3×

Where this comes from

Reported directly by NTHI in its filing.

Tagged under the XBRL concept nthi:OutstandingAmountsPayableToUscForClinicalTrialServices.

The official record: NTHI’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about NTHI's outstanding amounts payable to usc for clinical trial services.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NTHI's outstanding amounts payable to usc for clinical trial services?
NTHI (NTHI) reported outstanding amounts payable to usc for clinical trial services of $171.04K in Q1 2026.